Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update Journal Article
| Authors: | Giordano, S. H.; Temin, S.; Chandarlapaty, S.; Crews, J. R.; Esteva, F. J.; Kirshner, J. J.; Krop, I. E.; Levinson, J.; Lin, N. U.; Modi, S.; Patt, D. A.; Perlmutter, J.; Ramakrishna, N.; Winer, E. P.; Davidson, N. E. |
| Article Title: | Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update |
| Abstract: | PurposeTo update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer to 2018.MethodsAn Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events.ResultsOf the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations.RecommendationsHER2-targeted therapy is recommended for patients with HER2-positive advanced breast cancer, except for those with clinical congestive heart failure or significantly compromised left ventricular ejection fraction, who should be evaluated on a case-by-case basis. Trastuzumab, pertuzumab, and taxane for first-line treatment and trastuzumab emtansine for second-line treatment are recommended. In the third-line setting, clinicians should offer other HER2-targeted therapy combinations or trastuzumab emtansine (if not previously administered) and may offer pertuzumab if the patient has not previously received it. Optimal duration of chemotherapy is at least 4 to 6 months or until maximum response, depending on toxicity and in the absence of progression. HER2-targeted therapy can continue until time of progression or unacceptable toxicities. For patients with HER2-positive and estrogen receptor-positive/progesterone receptor-positive breast cancer, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine therapy plus HER2-targeted therapy or endocrine therapy alone. Additional information is available at www.asco.org/breast-cancer-guidelines. |
| Keywords: | care; american society |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 26 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-09-10 |
| Start Page: | 2736 |
| End Page: | 2740 |
| Language: | English |
| ACCESSION: | WOS:000445669600010 |
| DOI: | 10.1200/jco.2018.79.2697 |
| PROVIDER: | wos |
| PUBMED: | 29939838 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
265Modi -
277Chandarlapaty
Related MSK Work